Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2013

01.04.2013 | Epidemiology

The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study

verfasst von: Susan G. Lakoski, Carolyn E. Barlow, Graeme J. Koelwyn, Whitney E. Hornsby, Jesse Hernandez, Laura F. DeFina, Nina B. Radford, Samantha M. Thomas, James E. Herndon II, Jeffrey Peppercorn, Pamela S. Douglas, Lee W. Jones

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

We examined cardiorespiratory fitness (CRF) levels in early stage breast cancer patients and determined whether CRF differs as a function of adjuvant therapy regimen. A total of 180 early breast cancer patients representing three treatment groups (surgery only, single-, and multi-modality adjuvant therapy) in the Cooper Center Longitudinal Study (CCLS) were studied. A non-cancer control group (n = 180) matched by sex, age, and date of the CCLS visit was included. All subjects underwent an incremental exercise tolerance test to symptom limitation to assess CRF (i.e., peak metabolic equivalents [METs] and time to exhaustion). The mean time from breast cancer diagnosis to exercise tolerance testing was 7.4 ± 6.2 years. In adjusted analyses, time to exhaustion and peak METs were incrementally impaired with the addition of surgery, single-, and multi-modality adjuvant therapy compared to those of matched controls (p = 0.006 and 0.028, respectively). CRF was lowest in the multi-modality group compared to all other groups (all p’s < 0.05). Despite being 7 years post-diagnosis, asymptomatic early breast cancer survivors have marked reductions in CRF. Patients treated with multi-modal adjuvant therapy have the greatest impairment in CRF.
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29PubMedCrossRef Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRef
3.
Zurück zum Zitat Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50(15):1435–1441PubMedCrossRef Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50(15):1435–1441PubMedCrossRef
4.
Zurück zum Zitat Lakoski SG, Eves ND, Douglas PS, Jones LW (2012) Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 9(5):288–296PubMedCrossRef Lakoski SG, Eves ND, Douglas PS, Jones LW (2012) Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 9(5):288–296PubMedCrossRef
5.
Zurück zum Zitat Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol Off J Am Soc Clin Oncol 23(13):2900–2902CrossRef Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol Off J Am Soc Clin Oncol 23(13):2900–2902CrossRef
6.
Zurück zum Zitat Jannazzo A, Hoffman J, Lutz M (2008) Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 42(1):99–104PubMedCrossRef Jannazzo A, Hoffman J, Lutz M (2008) Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 42(1):99–104PubMedCrossRef
7.
Zurück zum Zitat Hsia CC, Ramanathan M, Estrera AS (1992) Recruitment of diffusing capacity with exercise in patients after pneumonectomy. Am Rev Respir Dis 145(4 Pt 1):811–816PubMedCrossRef Hsia CC, Ramanathan M, Estrera AS (1992) Recruitment of diffusing capacity with exercise in patients after pneumonectomy. Am Rev Respir Dis 145(4 Pt 1):811–816PubMedCrossRef
8.
Zurück zum Zitat Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS (2008) Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol 9(8):757–765PubMedCrossRef Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS (2008) Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol 9(8):757–765PubMedCrossRef
9.
Zurück zum Zitat Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, Drazner MH, de Lemos JA, Berry JD (2011) Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. Circulation 123(13):1377–1383PubMedCrossRef Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, Drazner MH, de Lemos JA, Berry JD (2011) Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. Circulation 123(13):1377–1383PubMedCrossRef
10.
Zurück zum Zitat Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE (2002) Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346(11):793–801PubMedCrossRef Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE (2002) Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346(11):793–801PubMedCrossRef
11.
Zurück zum Zitat Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW (1989) Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 262(17):2395–2401PubMedCrossRef Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW (1989) Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 262(17):2395–2401PubMedCrossRef
12.
Zurück zum Zitat Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA (1995) Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 273(14):1093–1098PubMedCrossRef Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA (1995) Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 273(14):1093–1098PubMedCrossRef
13.
Zurück zum Zitat Lakoski SG, Barlow CE, Farrell SW, Berry JD, Morrow JR Jr, Haskell WL (2011) Impact of body mass index, physical activity, and other clinical factors on cardiorespiratory fitness (from the Cooper Center Longitudinal Study). Am J Cardiol 108(1):34–39PubMedCrossRef Lakoski SG, Barlow CE, Farrell SW, Berry JD, Morrow JR Jr, Haskell WL (2011) Impact of body mass index, physical activity, and other clinical factors on cardiorespiratory fitness (from the Cooper Center Longitudinal Study). Am J Cardiol 108(1):34–39PubMedCrossRef
14.
Zurück zum Zitat Pollock ML, Foster C, Schmidt D, Hellman C, Linnerud AC, Ward A (1982) Comparative analysis of physiologic responses to three different maximal graded exercise test protocols in healthy women. Am Heart J 103(3):363–373PubMedCrossRef Pollock ML, Foster C, Schmidt D, Hellman C, Linnerud AC, Ward A (1982) Comparative analysis of physiologic responses to three different maximal graded exercise test protocols in healthy women. Am Heart J 103(3):363–373PubMedCrossRef
15.
Zurück zum Zitat Pollock ML, Bohannon RL, Cooper KH, Ayres JJ, Ward A, White SR, Linnerud AC (1976) A comparative analysis of four protocols for maximal treadmill stress testing. Am Heart J 92(1):39–46PubMedCrossRef Pollock ML, Bohannon RL, Cooper KH, Ayres JJ, Ward A, White SR, Linnerud AC (1976) A comparative analysis of four protocols for maximal treadmill stress testing. Am Heart J 92(1):39–46PubMedCrossRef
16.
Zurück zum Zitat Ho JS, Fitzgerald SJ, Barlow CE, Cannaday JJ, Kohl HW III, Haskell WL, Cooper KH (2010) Risk of mortality increases with increasing number of abnormal non-ST parameters recorded during exercise testing. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Cardiac Rehabil Exerc Physiol 17(4):462–468CrossRef Ho JS, Fitzgerald SJ, Barlow CE, Cannaday JJ, Kohl HW III, Haskell WL, Cooper KH (2010) Risk of mortality increases with increasing number of abnormal non-ST parameters recorded during exercise testing. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Cardiac Rehabil Exerc Physiol 17(4):462–468CrossRef
17.
Zurück zum Zitat Peel JB, Sui X, Adams SA, Hebert JR, Hardin JW, Blair SN (2009) A prospective study of cardiorespiratory fitness and breast cancer mortality. Med Sci Sports Exerc 41(4):742–748PubMedCrossRef Peel JB, Sui X, Adams SA, Hebert JR, Hardin JW, Blair SN (2009) A prospective study of cardiorespiratory fitness and breast cancer mortality. Med Sci Sports Exerc 41(4):742–748PubMedCrossRef
18.
Zurück zum Zitat Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32(9 Suppl):S498–S504PubMed Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32(9 Suppl):S498–S504PubMed
19.
Zurück zum Zitat Jones LW, Courneya KS, Mackey JR, Muss H, Pituskin EN, Scott JM, Hornsby WE, Coan AD, Herndon JE II, Douglas PS et al (2012) Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 30(20):2530–2537 Jones LW, Courneya KS, Mackey JR, Muss H, Pituskin EN, Scott JM, Hornsby WE, Coan AD, Herndon JE II, Douglas PS et al (2012) Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 30(20):2530–2537
20.
Zurück zum Zitat Froelicher VF Jr, Thompson AJ Jr, Davis G, Stewart AJ, Triebwasser JH (1975) Prediction of maximal oxygen consumption. Comparison of the Bruce and Balke treadmill protocols. Chest 68(3):331–336PubMedCrossRef Froelicher VF Jr, Thompson AJ Jr, Davis G, Stewart AJ, Triebwasser JH (1975) Prediction of maximal oxygen consumption. Comparison of the Bruce and Balke treadmill protocols. Chest 68(3):331–336PubMedCrossRef
21.
Zurück zum Zitat Hermansen L, Saltin B (1969) Oxygen uptake during maximal treadmill and bicycle exercise. J Appl Physiol 26(1):31–37PubMed Hermansen L, Saltin B (1969) Oxygen uptake during maximal treadmill and bicycle exercise. J Appl Physiol 26(1):31–37PubMed
22.
Zurück zum Zitat Khakoo AY, Yeh ET (2008) Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 5(11):655–667PubMedCrossRef Khakoo AY, Yeh ET (2008) Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 5(11):655–667PubMedCrossRef
23.
Zurück zum Zitat Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ et al (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76(3):656–665PubMedCrossRef Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ et al (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76(3):656–665PubMedCrossRef
24.
Zurück zum Zitat Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122–3131PubMedCrossRef Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122–3131PubMedCrossRef
25.
Zurück zum Zitat Hudson MM, Ness KK, Nolan VG, Armstrong GT, Green DM, Morris EB, Spunt SL, Metzger ML, Krull KR, Klosky JL et al (2011) Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 56(5):825–836PubMedCrossRef Hudson MM, Ness KK, Nolan VG, Armstrong GT, Green DM, Morris EB, Spunt SL, Metzger ML, Krull KR, Klosky JL et al (2011) Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 56(5):825–836PubMedCrossRef
Metadaten
Titel
The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study
verfasst von
Susan G. Lakoski
Carolyn E. Barlow
Graeme J. Koelwyn
Whitney E. Hornsby
Jesse Hernandez
Laura F. DeFina
Nina B. Radford
Samantha M. Thomas
James E. Herndon II
Jeffrey Peppercorn
Pamela S. Douglas
Lee W. Jones
Publikationsdatum
01.04.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2478-1

Weitere Artikel der Ausgabe 3/2013

Breast Cancer Research and Treatment 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.